Duyuru • Jul 01
Anhui Anke Biotechnology (Group) Co., Ltd. to Report First Half, 2026 Results on Aug 26, 2026 Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report first half, 2026 results on Aug 26, 2026 Declared Dividend • May 27
Dividend of CN¥0.25 announced Shareholders will receive a dividend of CN¥0.25. Ex-date: 29th May 2026 Payment date: 29th May 2026 Dividend yield will be 3.0%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is covered by both earnings (60% earnings payout ratio) and cash flows (61% cash payout ratio). The dividend has increased by an average of 20% per year over the past 10 years. However, payments have been volatile during that time. Earnings per share has grown by 11% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. Board Change • May 20
Less than half of directors are independent Following the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 8 non-independent directors. Independent Director Lu Shi Yao was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Duyuru • Dec 31
Anhui Anke Biotechnology (Group) Co., Ltd. to Report Fiscal Year 2025 Results on Mar 31, 2026 Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report fiscal year 2025 results on Mar 31, 2026 Duyuru • Sep 30
Anhui Anke Biotechnology (Group) Co., Ltd. to Report Q3, 2025 Results on Oct 28, 2025 Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report Q3, 2025 results on Oct 28, 2025 Duyuru • Jul 02
Anhui Anke Biotechnology (Group) Co., Ltd. to Report First Half, 2025 Results on Aug 22, 2025 Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report first half, 2025 results on Aug 22, 2025 Duyuru • Apr 23
Anhui Anke Biotechnology (Group) Co., Ltd. Approves Profit Distribution for 2024 Anhui Anke Biotechnology (Group) Co., Ltd. at its Annual General Meeting of 2024 held on 18 April 2025, approved 2024 profit distribution plan with Cash dividend/10 shares (tax included): CNY 1.50000000. Duyuru • Mar 31
Anhui Anke Biotechnology (Group) Co., Ltd. to Report Q1, 2025 Results on Apr 29, 2025 Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report Q1, 2025 results on Apr 29, 2025 Duyuru • Mar 30
Anhui Anke Biotechnology (Group) Co., Ltd. Proposes Final Cash Dividend for the Year 2024 Anhui Anke Biotechnology (Group) Co., Ltd. announced on 28 March 2025 the profit distribution proposal for 2024 as follows: Final Cash dividend per 10 shares (tax included) of CNY 1.50000000. Duyuru • Mar 28
Anhui Anke Biotechnology (Group) Co., Ltd., Annual General Meeting, Apr 18, 2025 Anhui Anke Biotechnology (Group) Co., Ltd., Annual General Meeting, Apr 18, 2025, at 09:30 China Standard Time. Location: The Company's Meeting Room, Hefei, Anhui China Duyuru • Jan 09
Anhui Anke Biotechnology (Group) Co., Ltd. Approves Cash Dividend for Third Quarter of 2024 Anhui Anke Biotechnology (Group) Co., Ltd. in its Extraordinary General Meeting of 2025 on 7 January 2025 approved Cash dividend/10 shares (tax included) of CNY 1.00000000 for third quarter of 2024. Duyuru • Dec 31
Anhui Anke Biotechnology (Group) Co., Ltd. to Report Fiscal Year 2024 Results on Mar 28, 2025 Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report fiscal year 2024 results on Mar 28, 2025 Duyuru • Dec 21
Anhui Anke Biotechnology (Group) Co., Ltd. Proposes Dividend for the Third Quarter of 2024 Anhui Anke Biotechnology (Group) Co., Ltd. announced on 20 December 2024 the profit distribution proposal for the third quarter of 2024 as follows: Cash dividend/10 shares (tax included): CNY 1.0. Reported Earnings • Oct 25
Third quarter 2024 earnings released: EPS: CN¥0.10 (vs CN¥0.15 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.10 (down from CN¥0.15 in 3Q 2023). Revenue: CN¥622.5m (down 15% from 3Q 2023). Net income: CN¥173.6m (down 33% from 3Q 2023). Profit margin: 28% (down from 35% in 3Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Oct 15
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥8.99, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 25x in the Biotechs industry in China. Total loss to shareholders of 24% over the past three years. Duyuru • Sep 30
Anhui Anke Biotechnology (Group) Co., Ltd. to Report Q3, 2024 Results on Oct 25, 2024 Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report Q3, 2024 results on Oct 25, 2024 Valuation Update With 7 Day Price Move • Sep 27
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to CN¥8.73, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 21x in the Biotechs industry in China. Total loss to shareholders of 21% over the past three years. Reported Earnings • Aug 28
Second quarter 2024 earnings released: EPS: CN¥0.12 (vs CN¥0.13 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.12 (down from CN¥0.13 in 2Q 2023). Revenue: CN¥642.7m (down 7.3% from 2Q 2023). Net income: CN¥198.4m (down 5.9% from 2Q 2023). Profit margin: 31% (in line with 2Q 2023). Revenue is forecast to grow 24% p.a. on average during the next 2 years, compared to a 24% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. Duyuru • Jun 29
Anhui Anke Biotechnology (Group) Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024 Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report first half, 2024 results on Aug 28, 2024 Declared Dividend • May 23
Dividend of CN¥0.25 announced Dividend of CN¥0.25 is the same as last year. Ex-date: 27th May 2024 Payment date: 27th May 2024 Dividend yield will be 2.5%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is covered by both earnings (47% earnings payout ratio) and cash flows (59% cash payout ratio). The dividend has increased by an average of 22% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 16% over the next year, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Apr 26
First quarter 2024 earnings released: EPS: CN¥0.13 (vs CN¥0.11 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.13 (up from CN¥0.11 in 1Q 2023). Revenue: CN¥656.1m (up 10% from 1Q 2023). Net income: CN¥217.7m (up 17% from 1Q 2023). Profit margin: 33% (up from 31% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 21% p.a. on average during the next 2 years, compared to a 22% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings. Duyuru • Mar 30
Anhui Anke Biotechnology (Group) Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024 Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report Q1, 2024 results on Apr 26, 2024 Duyuru • Mar 28
Anhui Anke Biotechnology (Group) Co., Ltd., Annual General Meeting, Apr 18, 2024 Anhui Anke Biotechnology (Group) Co., Ltd., Annual General Meeting, Apr 18, 2024, at 09:30 China Standard Time. Location: The Company's Meeting Room, Hefei, Anhui China Reported Earnings • Mar 28
Full year 2023 earnings released: EPS: CN¥0.51 (vs CN¥0.43 in FY 2022) Full year 2023 results: EPS: CN¥0.51 (up from CN¥0.43 in FY 2022). Revenue: CN¥2.87b (up 23% from FY 2022). Net income: CN¥847.2m (up 21% from FY 2022). Profit margin: 30% (in line with FY 2022). Revenue is forecast to grow 19% p.a. on average during the next 2 years, compared to a 23% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Feb 07
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to CN¥9.84, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 20x in the Biotechs industry in China. Total loss to shareholders of 20% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥17.03 per share. Duyuru • Dec 29
Anhui Anke Biotechnology (Group) Co., Ltd. to Report Fiscal Year 2023 Results on Mar 28, 2024 Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report fiscal year 2023 results on Mar 28, 2024 Board Change • Oct 27
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 8 non-independent directors. Independent Director Feihu Chen was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 25
Third quarter 2023 earnings released: EPS: CN¥0.15 (vs CN¥0.15 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.15 (up from CN¥0.15 in 3Q 2022). Revenue: CN¥734.1m (up 17% from 3Q 2022). Net income: CN¥258.1m (up 3.3% from 3Q 2022). Profit margin: 35% (down from 40% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 24% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Duyuru • Sep 30
Anhui Anke Biotechnology (Group) Co., Ltd. to Report Q3, 2023 Results on Oct 25, 2023 Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report Q3, 2023 results on Oct 25, 2023 Reported Earnings • Aug 24
Second quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.10 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.13 (up from CN¥0.10 in 2Q 2022). Revenue: CN¥693.1m (up 27% from 2Q 2022). Net income: CN¥210.7m (up 23% from 2Q 2022). Profit margin: 30% (in line with 2Q 2022). Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. Reported Earnings • Mar 29
Full year 2022 earnings released: EPS: CN¥0.43 (vs CN¥0.13 in FY 2021) Full year 2022 results: EPS: CN¥0.43 (up from CN¥0.13 in FY 2021). Revenue: CN¥2.33b (up 7.5% from FY 2021). Net income: CN¥703.3m (up 240% from FY 2021). Profit margin: 30% (up from 9.5% in FY 2021). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 27% p.a. on average during the next 2 years, compared to a 24% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Dec 13
Investor sentiment improved over the past week After last week's 15% share price gain to CN¥11.39, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 30x in the Biotechs industry in China. Total returns to shareholders of 22% over the past three years. Board Change • Nov 16
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 4 independent directors. 8 non-independent directors. Non-Independent Director Zhen Xu was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Reported Earnings • Oct 27
Third quarter 2022 earnings released: EPS: CN¥0.15 (vs CN¥0.11 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.15 (up from CN¥0.11 in 3Q 2021). Revenue: CN¥626.0m (up 8.3% from 3Q 2021). Net income: CN¥249.8m (up 35% from 3Q 2021). Profit margin: 40% (up from 32% in 3Q 2021). Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Reported Earnings • Aug 26
Second quarter 2022 earnings released: EPS: CN¥0.10 (vs CN¥0.075 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.10 (up from CN¥0.075 in 2Q 2021). Revenue: CN¥547.4m (up 13% from 2Q 2021). Net income: CN¥171.5m (up 45% from 2Q 2021). Profit margin: 31% (up from 24% in 2Q 2021). Over the next year, revenue is forecast to grow 32%, compared to a 33% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Reported Earnings • Apr 29
First quarter 2022 earnings released: EPS: CN¥0.11 (vs CN¥0.075 in 1Q 2021) First quarter 2022 results: EPS: CN¥0.11 (up from CN¥0.075 in 1Q 2021). Revenue: CN¥533.4m (up 10.0% from 1Q 2021). Net income: CN¥172.9m (up 38% from 1Q 2021). Profit margin: 32% (up from 26% in 1Q 2021). Over the next year, revenue is forecast to grow 28%, compared to a 47% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Board Change • Apr 27
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 4 independent directors. 8 non-independent directors. Non-Independent Director Zhen Xu was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Reported Earnings • Apr 03
Full year 2021 earnings released: EPS: CN¥0.13 (vs CN¥0.22 in FY 2020) Full year 2021 results: EPS: CN¥0.13 (down from CN¥0.22 in FY 2020). Revenue: CN¥2.17b (up 28% from FY 2020). Net income: CN¥206.6m (down 42% from FY 2020). Profit margin: 9.5% (down from 21% in FY 2020). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Jan 21
Investor sentiment deteriorated over the past week After last week's 20% share price decline to CN¥11.27, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 34x in the Biotechs industry in China. Total returns to shareholders of 38% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥18.44 per share. Reported Earnings • Oct 31
Third quarter 2021 earnings released: EPS CN¥0.11 (vs CN¥0.084 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥578.2m (up 31% from 3Q 2020). Net income: CN¥185.4m (up 36% from 3Q 2020). Profit margin: 32% (up from 31% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth. Reported Earnings • Aug 22
Second quarter 2021 earnings released: EPS CN¥0.075 (vs CN¥0.049 in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥484.4m (up 22% from 2Q 2020). Net income: CN¥118.4m (up 46% from 2Q 2020). Profit margin: 24% (up from 20% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 5% per year whereas the company’s share price has increased by 9% per year. Valuation Update With 7 Day Price Move • May 24
Investor sentiment deteriorated over the past week After last week's 16% share price decline to CN¥15.00, the stock trades at a forward P/E ratio of 44x. Average forward P/E is 47x in the Biotechs industry in China. Total returns to shareholders of 27% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥22.34 per share. Reported Earnings • Apr 30
First quarter 2021 earnings released: EPS CN¥0.09 (vs CN¥0.062 in 1Q 2020) The company reported a solid first quarter result with improved earnings and revenues, although profit margins were flat. First quarter 2021 results: Revenue: CN¥484.8m (up 54% from 1Q 2020). Net income: CN¥125.6m (up 54% from 1Q 2020). Profit margin: 26% (in line with 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings. Reported Earnings • Apr 08
Full year 2020 earnings released: EPS CN¥0.26 (vs CN¥0.092 in FY 2019) The company reported a decent full year result with improved earnings and profit margins, although revenues were flat. Full year 2020 results: Revenue: CN¥1.70b (flat on FY 2019). Net income: CN¥359.0m (up 188% from FY 2019). Profit margin: 21% (up from 7.3% in FY 2019). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings. Is New 90 Day High Low • Feb 06
New 90-day low: CN¥13.69 The company is down 17% from its price of CN¥16.55 on 06 November 2020. The Chinese market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥3.91 per share. Is New 90 Day High Low • Dec 28
New 90-day low: CN¥14.64 The company is down 10.0% from its price of CN¥16.21 on 30 September 2020. The Chinese market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥3.83 per share. Is New 90 Day High Low • Dec 12
New 90-day low: CN¥14.71 The company is down 7.0% from its price of CN¥15.90 on 11 September 2020. The Chinese market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥3.87 per share. Is New 90 Day High Low • Nov 25
New 90-day low: CN¥15.69 The company is down 8.0% from its price of CN¥17.10 on 27 August 2020. The Chinese market is up 1.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥3.43 per share. Reported Earnings • Oct 29
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥166.6m, down 42% from the prior year. Total revenue was CN¥1.70b over the last 12 months, up 5.9% from the prior year. 
